James M. Foran, MD, FRCPC - Landmarks Across the Patient Journey in AML: Applying Evidence With Novel Therapeutics Pre- and Post-AlloHCT

Go online to PeerView.com/HJG860 to view the activity, download
slides and practice aids, and complete the post-test to earn
credit. New science has dramatically altered the current clinical
consensus on personalized care for HCT-eligible AML patients and
supported the use of a variety of options (depending on a patient’s
baseline characteristics). In this activity from the 2022 Tandem
meetings, our expert panelists use a case-based format to tackle
these new developments and provide instruction on how to integrate
novel targeted, HMA, and antibody-based options into the management
of HCT-eligible AML. Throughout, they provide insights on how to
choose appropriate induction, conditioning, post-remission, and
maintenance options, as well as discuss treatment plans for
relapsed/refractory disease. Watch this program to see how novel
therapeutics are changing paradigms and challenging long-standing
practices in the management of HCT-eligible AML. Upon completion of
this activity, participants should be better able to: Identify
baseline clinical and molecular factors that can inform prognosis
and treatment decisions for transplant-eligible patients with acute
myeloid leukemia (AML), Employ modern therapeutics as components of
personalized induction, consolidation, and
maintenance/post-remission regimens for transplant-eligible
patients with AML in accordance with updated safety and efficacy
evidence and current guidelines, Integrate novel therapeutics into
the management of patients with relapsed/refractory (R/R) AML,
including as pre-transplant conditioning or as salvage options
post-HCT.